Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Pneumonia. Treatment and Diagnosis
Mattila, Joshua T. , Fine, Michael J. , Murray, Patrick R. , Chen, Bill B. , Lin, Philana Ling , Limper, Andrew H.

Annals of the American Thoracic Society | August 22, 2014 | Volume: 11 | Issue: Supplement_4 | Pages: S189-S192

10.1513/annalsats.201401-027pl | PMID 25148424 Get It

Abstract Pneumonia remains a leading cause of morbidity and mortality despite advances in treatment and therapy. The “Pneumonia: Treatment and Diagnosis” session of the Pittsburgh International Lung Conference examined topics related to improving care of patients with pneumonia. These topics included the process and quality of care for community-acquired pneumonia (CAP), diagnosis and treatment of emerging fungal pathogens, an overview of the strengths and weaknesses of different diagnostic modalities, and an example of how basic science is exploring immunomodulatory strategies for pneumonia treatment. Systematic health care provider and institutional improvements can decrease mortality rates in CAP, particularly in patients with increasingly complex comorbidities. Aspects of current guidelines for the diagnosis and treatment of fungal pneumonia were reviewed through a series of case presentations. Proper treatment of pneumonia hinges on correct pathogen identification but is complicated by the variety of diagnostic assays with variable specificity, sensitivity, and interpretation. In addressing this topic, Dr. Patrick Murray, Ph.D., discussed a range of diagnostic tests for a variety of pathogens and guidelines for their use. In addition to the current state of CAP treatment, Bill (Beibei) Chen, M.D., Ph.D., presented a new potential therapeutic agent called forsythin, an immunomodulatory compound derived from a plant used in traditional Chinese medicine. These topics, ranging from institution-sized policy to interactions at the molecular scale, paint a broad perspective of the efforts against pneumonia.
Phase I‐II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
Reece, Donna , Atenafu, Eshetu G. , Jiménez‐Zepeda, Víctor H. , Anglin, Peter, Chen, Christine , Kukreti, Vishal , Trudel, Suzanne , Masih‐Khan, Esther , Mıkhael, Joseph

British Journal of Haematology | August 22, 2014 | Volume: 168 | Issue: 1 | Pages: 46-54

10.1111/bjh.13100 | PMID 25146584 Get It

SummaryThis single institution, open label Phase I‐II dose escalation trial evaluated the safety and efficacy of the combination of lenalidomide (Revlimid®), cyclophosphamide and prednisone (CPR) in patients with relapsed/refractory multiple myeloma. The maximal administered dose of CPR consisted of cyclophosphamide 300 mg/m2 on day 1, 8, and 15, lenalidomide 25 mg on d 1–21 and prednisone 100 mg every other day in a 28‐d cycle. Between November 2007 and June 2009, 32 patients were entered in cohorts of three at three dose levels. The median age was 64 years, 59% were male, with a median two prior regimens. Responding patients could stay on treatment until progression. The full‐dose CPR regimen produced no dose‐limiting toxicity and was delivered for a median of 16 months (3·5–65 months) with acceptable safety and tolerance. The overall response rate (≥ partial response) was 94% at a median follow up of 28 months. The median progression‐free survival was 16·1 months [95% confidence interval (CI); 10·9–22·5 months], while the median overall survival was 27·6 months (95% CI; 16·8–36·6 months). Only the beta‐2 microglobulin level at protocol entry correlated with a better survival (P = 0·047). These observations compare favourably with other 2‐ and 3‐ drug combinations for relapsed/refractory myeloma, and suggest that CPR should be evaluated further in the setting of relapsed/refractory disease, or in newly diagnosed patients.
A Fuzzy Mathematical Model Determining the Risk for Carotid Intima-Medial Thickness in Recently Menopausal Women Enrolled in the KEEPS Study
Shepherd, Alex J. , Miller, Virginia M. , Jayachandran, Muthuvel , Malik, D. S., Mordeson, John N. , Hunter, Larry W.

New Mathematics and Natural Computation | August 22, 2014 | Volume: 10 | Issue: 03 | Pages: 187-201

10.1142/s1793005714500100 Get It

Carotid intima-medial thickness (CIMT) allows for early detection of carotid atherosclerotic vascular disease. Using fuzzy logic techniques, we propose a model for calculating the risk for predicting CIMT using expert opinion and various factors associated with CIMT in recently menopausal women. Study participants were enrolled in the Kronos Early Estrogen Prevention Study (KEEPS), a four year study where participants were assigned to either oral or transdermal hormone therapy or to the placebo group. The fuzzy mathematical model uses five fuzzy logic methods to calculate this risk factor for CIMT, including the analytic hierarchy process (AHP) method, Guiasu method, Yen method, Dempster–Shafer (DS) method, and the set valued statistical method (SVSM). The four methods, AHP, Guiasu, Yen, DS, and SVSM, were correlated to each other according to the Pearson ranking method. In addition, results showed that the estrogen treatment groups showed a statically significant decrease in calculated CIMT risk compared to placebo when all the methods were combined together (p = 0.0017). Our fuzzy mathematical model provides the first fuzzy mathematical model to predict the risk of CIMT in recently menopausal women and menopausal hormone therapy may be beneficial in reducing this risk.
Trigeminal trophic syndrome: A rare cause of chronic facial pain and skin ulcers
Golden, Erin C., Robertson, Carrie E. , Moossy, John, Sandroni, Paola , Garza, Ivan , Golden, Erin, Robertson, Carrie E

Cephalalgia | August 22, 2014 | Volume: 35 | Issue: 7 | Pages: 636-636

10.1177/0333102414547140 | PMID 25147332 Get It

Antineoplastic Agents and the Associated Myelosuppressive Effects
Barreto, Jason N. , McCullough, Kristen , Ice, Lauren L., Smith, Judith A. , McCullough, Kristen B, McCullough, Kristen B

Journal of Pharmacy Practice | August 21, 2014 | Volume: 27 | Issue: 5 | Pages: 440-446

10.1177/0897190014546108 | PMID 25147158 Get It

Bone marrow is a complex organ responsible for the regulation of hematopoietic cell distribution throughout the human body. Patients receiving antineoplastic agents as a therapeutic intervention for hematologic malignancy often experience varying degrees of myelotoxicity. Antineoplastic agents cause hypocellularity in marrow resulting in a reduction in hematopoietic tissue activity and a corresponding decline in cell production. Quantifying the adverse effects on hematopoiesis is based on the properties of a single agent, the use of individual drugs within a combination chemotherapy regimen, and the course, or courses, of chemotherapy designed to treat cancer. The direct or indirect suppression of erythrocytes, granulocytes, and megakaryocytes has potential for multiple negative clinical consequences ranging from increased monitoring of blood counts to life-threatening infection and death. This review will provide an overview of the structure and function of competent adult bone marrow, describe the process of hematopoiesis, and characterize the myelotoxicities associated with common antineoplastic agents currently used in the treatment of cancer.
Response to Comments on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345
Zhang, Yuanhui , Mason, Jennifer, Smith, Steven A., Shah, Nilay D. , McCoy, Rozalina G. , Denton, Brian T.

Diabetes Care | August 21, 2014 | Volume: 37 | Issue: 9 | Pages: e206-e207

10.2337/dc14-1339 | PMID 25147267 Get It

Ability of Circulating Human Hematopoietic Lineage Negative Cells to Support Hematopoiesis
Peris, Pilar , Roforth, Matthew M., Nicks, Kristy M., Fraser, Daniel G., Fujita, Koji , Jilka, Robert L., McGregor, Ulrike, Khosla, Sundeep

Journal of Cellular Biochemistry | August 21, 2014 | Volume: 116 | Issue: 1 | Pages: 58-66

10.1002/jcb.24942 | PMID 25145595 Get It

AbstractHematopoietic stem cell (HSC) self‐renewal is regulated by osteoblast and/or endothelial cells within the hematopoietic niche. However, the true identity of the supporting cells and the nature of the secreted factors remain uncertain. We developed a novel mouse model and analyzed whether circulating human peripheral hematopoietic lineage negative/AP+ (lin−/AP+) cells support hematopoiesis in vivo. Thus, immunocompromised (Rag) mice expressing thymidine kinase (Tk) under the control of the 3.6Col1α1 promoter (Tk‐Rag) were treated with ganciclovir, resulting in osteoblast progenitor cell ablation and subsequent loss of hematopoiesis (evaluated by measuring mouse Ter119+ erythroid cells). Following hematopoietic cell depletion, human bone marrow‐derived marrow stromal cells (MSCs) or lin−/AP+ cells were infused into Tk‐Rag mice and compared with saline infusions. Ganciclovir significantly reduced (7.4‐fold) Ter119+ cells in the bone marrow of Tk‐Rag mice compared to saline injections. Infusion of either MSCs or lin−/AP+ cells into ganciclovir‐treated mice resulted in a 3.3‐fold and 2.7‐fold increase (P < 0.01), respectively, in Ter119+ cells compared to mice receiving saline. Relative to lin−/AP− cells, lin−/AP+ cells expressed high levels of mesenchymal, endothelial, and hematopoiesis supporting genes. Thus, human peripheral blood lin−/AP+ cells represent a novel cell type capable of supporting hematopoiesis in a manner comparable to MSCs. J. Cell. Biochem. 116: 58–66, 2015. © 2014 Wiley Periodicals, Inc.
Faculty Opinions recommendation of The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice.
Jelinek, Diane F.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718530531.793498917 Get It

Faculty Opinions recommendation of Structural basis for activity of highly efficient RNA mimics of green fluorescent protein.
Maher, Jim

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 21, 2014 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.718490434.793498931 Get It